The 68 references in paper S. Avdeev N., С. Авдеев Н. (2015) “Можно ли улучшить прогноз у больных хронической обструктивной болезнью легких? // Is it possible to improve prognosis in patients with chronic obstructive pulmonary disease?” / spz:neicon:pulmonology:y:2015:i:4:p:469-476

1
Lopez A.D., Shibuya K., Rao C. et al. Chronic obstructive pulmonary disease: current burden and future projection. Eur. Respir. J.2006; 27: 397–412.
(check this in PDF content)
2
Mathers C.D., Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;
(check this in PDF content)
3
e442. 3. Buist A.S., McBurnie M.A., Vollmer W.M. et al. International variation in the prevalence of COPD (the BOLD Study): a population\nbased prevalence study. Lancet. 2007; 370: 741–750.
(check this in PDF content)
4
Жестков А.В., Косарев В.В., Бабанов С.А., Глазитов А.В. Эпидемиология и факторы риска хронической обструктивной болезни легких в крупном промышлен\n ном центре Среднего Поволжья. Профилактика заболеваний и укрепление здоровья.2009; 1: 42–44. / Zhest\n kov A.V., Kosarev V.V., Babanov S.A., Glazitov A.V. Epidemiology and risk factors of chronic obstructive pul\n monary disease in a large industrial center of the Middle Volga region. Profilaktika zabolevaniy i ukreplenie zdorov'ya. 2009; 1: 42–44 (in Russian).
(check this in PDF content)
5
Chuchalin A.G., Khaltaev N., Antonov N.S. et al. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. Intern. J. COPD.2014; 9: 963–974.
(check this in PDF content)
6
Global Initiative for Chronic Obstructive Lung Diseas (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI / WHO workshop report. The 2015 report is avail\n able on www.goldcopd.com
(check this in PDF content)
7
Hoyert D.L., Xu J. Deaths: preliminary data for 2011. Natl. Vital. Stat. Rep.2012; 61: 1–51.
(check this in PDF content)
8
Mannino D.M., Homa D.M., Akinbami L.J. et al. Chronic Obstructive Pulmonary Disease Surveillance – United States, 1971–2000. MMWR Surveillance Summaries.2002; 51 (SS06): 1–16.
(check this in PDF content)
9
Burney P.G.J., Patel J., Newson R. et al. Global and region\n al trends in COPD mortality, 1990–2010. Eur. Respir. J. 2015; 45: 1239–1247.
(check this in PDF content)
10
Garcia I.S., Clarа P.C. Causes of death and prediction of mortality in COPD. Arch. Bronconeumol.2010; 46: 343–346.
(check this in PDF content)
11
Fuso L., Incalzi R.A., Pistelli R. et al. Predicting mortality of patients hospitalized for acutely exacerbated chronic obstruc\n tive pulmonary disease. Am. J. Med.1995; 98: 272–277.
(check this in PDF content)
12
Vestbo J., Prescott E., Lange P. et al. Vital prognosis after hospitalization for COPD: a study of a random population sample.Respir. Med.1998; 92: 772–776.
(check this in PDF content)
13
Hansen E.F., Phanareth K., Laursen L.C. et al. Reversible and irreversible airflow obstruction as predictor of overall mortality in asthma and chronic obstructive pulmonary dis\n ease. Am. J. Respir. Crit. Care Med. 1999; 159: 1267–1271.
(check this in PDF content)
14
Martinez F.J., Foster G., Curtis J.L. et al. Predictors of mor\n tality in patients with emphysema and severe airflow obstruc\n tion. Am. J. Respir. Crit. Care Med.2006; 173: 1326–1334.
(check this in PDF content)
15
Ries A.L., Kaplan R.M., Limberg T.M., Prewitt L.M. Effects of pulmonary rehabilitation on physiologic and psy\n chosocial outcomes in patients with chronic obstructive pul\n monary disease. Ann. Intern. Med. 1995; 122: 823–832.
(check this in PDF content)
16
Anthonisen N.R., Wright E.C., Hodgkin J.E. Prognosis in chronic obstructive pulmonary disease. Am. Rev. Respir. Dis. 1986; 133: 14–20.
(check this in PDF content)
17
Tantucci C., Donati P., Nicosia F. et al. Inspiratory capaci\n ty predicts mortality in patients with chronic obstructive pulmonary disease. Respir. Med. 2008; 102: 613–619.
(check this in PDF content)
18
Casanova C., Cote C., de Torres J.P. et al. Inspiratory\nto\n total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease.Am. J. Respir. Crit. Care Med. 2005; 171: 591–597.
(check this in PDF content)
19
Boushy S.F., Coates E.D., Prognostic valie of pulmonary function tests in emphysema: with special reference to arte\n rial blood studies.Am. Rev. Respir. Dis. 1964; 90: 553–563.
(check this in PDF content)
20
Kanner R.E., Renzetti A.D., Stanish W.M. et al. Predictors of survival in subjects with chronic airflow limitation.Am. J. Med.1983; 74: 249–255.
(check this in PDF content)
21
Nizet T.A.C., van den Elshout F.J.J., Heijdra Y.F. et al. Survival of chronic hypercapnic COPD patients is predicted by smoking habits, comorbidity, and hypoxemia. Chest. 2005; 127: 1904–1910.
(check this in PDF content)
22
Cooper C.B., Waterhouse J., Howard P. Twelve year clinical study of patients with hypoxic cor pulmonale given long term domiciliary oxygen therapy. Thorax. 1987; 42: 105–110.
(check this in PDF content)
23
Ahmadi Z., Bornefalk\nHermansson A., Franklin K.A. et al. Hypo\n and hypercapnia predict mortality in oxygen\n dependent chronic obstructive pulmonary disease: a popu\n lation\nbased prospective study. Respir. Res.2014, 15: 30.
(check this in PDF content)
24
Burrows B., Kettel L.J., Niden A.H., Rabinowitz M., Diener C.F. Patterns of cardiovascular dysfunction in chronic obstructive lung disease. N. Engl. J. Med. 1972; 286: 912–918.
(check this in PDF content)
25
Weitzenblum E., Hirth C., Ducolone A. et al. Prognostic value of pulmonary artery pressure in chronic obstructive pulmonary disease. Thorax. 1981; 36: 752–758.
(check this in PDF content)
26
Chaouat A., Bugnet A.S., Kadaoui N. et al. Severe pul\n monary hypertension and chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2005; 172: 189–194.
(check this in PDF content)
27
Schols A.M., Slangen J., Volovics L.,Wouters E.F. Weight loss is a reversible factor in the prognosis of chronic obstruc\n tive pulmonary disease. Am. J. Respir. Crit. Care Med.1998; 157: 1791–1797.
(check this in PDF content)
28
Landbo C., Prescott E., Lange P., Vestbo J., Almdal T.P. Prognostic value of nutritional status in chronic obstructive pulmonary disease.Am. J. Respir. Crit. Care Med.1999; 160: 1856–1861.
(check this in PDF content)
29
Oga T., Nishimura K., Tsukino M., Sato S., Hajiro T. Ana\n lysis of the factors related to mortality in chronic obstructive pulmonary disease: role of exercise capacity and health sta\n tus.Am. J. Respir. Crit. Care Med. 2003; 167: 544–549.
(check this in PDF content)
30
Soler\nCataluna J.J., Martinez\nGarcia M.A., Roman S.P. et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005; 60: 925–931.
(check this in PDF content)
31
Suissa S., Dell'aniello S., Ernst P. Long\nterm natural histo\n ry of chronic obstructive pulmonary disease: severe exacer\n bations and mortality. Thorax. 2012; 67: 957–963.
(check this in PDF content)
32
Divo M., Cote C., de Torres J.P. et al. Comorbidities and risk of mortality in patients with chronic obstructive pul\n monary disease. Am. J. Respir. Crit. Care Med.2012; 186: 155–161.
(check this in PDF content)
33
Engstrom G., Lind P., Hedblad B. et al. Lung function and cardiovascular risk: relationship with inflammation\nsensi\n tive plasma proteins. Circulation. 2002; 106: 2555–2560.
(check this in PDF content)
34
Sin D.D., Man S.F. Why are patients with chronic obstruc\n tive pulmonary disease at increased risk of cardiovascular diseases? Circulation. 2003; 107: 1514–1519.
(check this in PDF content)
35
Rossi A., Aisanov Z., Avdeev S. et al. Mechanisms, assess\n ment and therapeutic implications of lung hyperinflation in COPD.Respir. Med.2015; 109: 785–802.
(check this in PDF content)
36
Zielinski J., MacNee W., Wedzicha J. et al. Causes of death in patients with COPD and chronic respiratory failure. Monaldi Arch. Chest Dis.1997; 52: 43–47.
(check this in PDF content)
37
Seneff M.G., Wagner D.P., Wagner R.P. et al. Hospital and 1\nyear survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary disease. JAMA. 1995; 274: 1852–1857.
(check this in PDF content)
38
Almagro P., Calbo E., Ochoa de Echaguen A. et al. Mortality after hospitalization for COPD. Chest. 2002; 121: 1441–1448.
(check this in PDF content)
39
Connors A.F., Dawson N.V., Thomas C. et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments).Am. J. Respir. Crit. Care Med.1996; 154: 959–967.
(check this in PDF content)
40
Wouters E.F. The burden of COPD in The Netherlands: results from the confronting COPD survey. Respir. Med. 2003; 97 (Suppl. C): S51–59.
(check this in PDF content)
41
Gunen H., Hacievliyagil S.S., Kosar F. et al. Factors affect\n ing survival of hospitalised patients with COPD. Eur. Respir. J.2005; 26: 234–241.
(check this in PDF content)
42
Kong G.K., Belman M.J., Weingarten S. Reducing length of stay for patients hospitalized with exacerbation of COPD by using a practice guideline. Chest. 1997; 111: 89–94.
(check this in PDF content)
43
Boushy S.F., Coates E.D., Prognostic valie of pulmonary function tests in emphysema: with special reference to arte\n rial blood studies.Am. Rev. Respir. Dis. 1964; 90: 553–563.
(check this in PDF content)
44
Kanner R.E., Renzetti A.D., Stanish W.M. et al. Predictors of survival in subjects with chronic airflow limitation. Am. J. Med. 1983; 74: 249–255.
(check this in PDF content)
45
Medical Research Council Working Party. Long term domi\n ciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet. 1981; i: 681–686.
(check this in PDF content)
46
Nocturnal Oxygen Therapy Trial Group: Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial.Ann. Intern. Med.1980; 93: 391–398.
(check this in PDF content)
47
McEvoy R.D., Pierce R.J., Hillman D. et al. Nocturnal non\ninvasive nasal ventilation in stable hypercapnic COPD: a randomised controlled trial. Thorax. 2009; 64: 561–566.
(check this in PDF content)
48
Kóhnlein T., Windisch W., Kóhler D. et al. Non\ninvasive positive pressure ventilation for the treatment of severe sta\n ble chronic obstructive pulmonary disease: a prospective, multicentre, randomised, controlled clinical trial. Lancet Respir. Med.2014; 2: 698–705.
(check this in PDF content)
49
Lahzami S., Bridevaux P.O., Soccal P.M. et al. Survival impact of lung transplantation for COPD. Eur. Respir. J. 2010; 36: 74–80.
(check this in PDF content)
50
Short P.M., Williamson P.A., Elder D.H. et al. The impact of tiotropium on mortality and exacerbations when added to inhaled corticosteroids and long\nacting β\nagonist therapy in COPD. Chest. 2012; 141: 81–86.
(check this in PDF content)
51
Tashkin D.P., Celli B., Senn S. et al. A 4\nyear trial of tiotropium in chronic obstructive pulmonary disease. N. Engl. J. Med.2008; 359: 1543–1554.
(check this in PDF content)
52
Celli B., Decramer M., Leimer I. et al. Cardiovascular safe\n ty of tiotropium in patients with COPD. Chest. 2010; 137; 20–30.
(check this in PDF content)
53
Neff A.L., Petty T.A. Long\nterm continuous oxygen therapy in chronic airway obstruction: mortality in relation to cor pulmonale, hypoxia and hypercapnia. Ann. Intern. Med. 1970; 72: 621–626.
(check this in PDF content)
54
Elliot M.W. Non\ninvasive ventilation in chronic obstructive pulmonary disease. In: Simonds A.K., ed. Non\nInvasive Respiratory Support, 3rded. London: Hodder Arnold; 2007.
(check this in PDF content)
55
Leger P., Bedicam J.M., Cornette A. et al. Nasal intermit\n tent positive pressure ventilation. Long\nterm follow\nup in patients with severe chronic respiratory insufficiency. Chest. 1994; 105: 100–105.
(check this in PDF content)
56
Strumpf D.A., Millman R.P., Carlisle C.C. et al. Nocturnal positive\npressure ventilation via nasal mask in patients with severe chronic obstructive pulmonary disease. Am. Rev. Respir. Dis. 1991; 144: 1234–1239.
(check this in PDF content)
57
Marin J.M., Soriano J.B., Carrizo S.J. et al. Outcomes in patients with chronic obstructive pulmonary disease and obstructive sleep apnea: the overlap syndrome. Am. J. Respir. Crit. Care Med. 2010; 182: 325–331.
(check this in PDF content)
58
Hogg J.C. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet. 2004; 364: 709–721.
(check this in PDF content)
59
Pauwels R.A., Lofdahl C.G., Laitinen L.A. et al. Long\nterm treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smok\n ing. European Respiratory Society Study on Chronic Obst\n ructive Pulmonary Disease.N. Engl. J. Med. 1999; 340: 1948–1953.
(check this in PDF content)
60
Burge P.S., Calverley P.M., Jones P.W. et al. Randomised, double blind, placebo controled study of fluticasone propi\n onate in patients with moderate to severe chronic obstruc\n tive pulmonary disease: the ISOLDE trial.Br. Med. J.2000; 320: 1297–1303.
(check this in PDF content)
61
Lung Health Study Research Group. Effect of inhaled tri\n amcinolone on the decline in pulmonary function in chron\n ic obstructive pulmonary disease. N. Engl. J. Med.2000; 343: 1902–1909.
(check this in PDF content)
62
Lofdahl C.G., Postma D.S., Pride N.B. et al. Possible pro\n tection by inhaled budesonide against ischaemic cardiac events in mild COPD. Eur. Respir. J. 2007; 29: 1115–1119.
(check this in PDF content)
63
Calverley P.M., Anderson J.A., Celli B. et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med.2007; 356: 775–789.
(check this in PDF content)
64
Yohannes A.M., Connolly M., Hanania N.A. Ten years of tiotropium: clinical impact and patient perspectives. Int. J. Chron. Obstruct. Pulm. Dis. 2013; 8: 117–125.
(check this in PDF content)
65
Gershon A.S., Wang L., To T. et al. Survival with tiotropium compared to long\nacting beta\n2\nagonists in chronic obstructive pulmonary disease. J. COPD. 2008; 5: 229–234.
(check this in PDF content)
66
Lipworth B.J., Short P.M. Explaining differential effects of tiotropium on mortality in COPD. Thorax. 2013; 68: 589–590.
(check this in PDF content)
67
Jenkins C.R., Beasley R. Tiotropium Respimat increases the risk of mortality. Thorax. 2013; 68: 5–7.
(check this in PDF content)
68
Wise R.A., Anzueto A., Cotton D. et al. Tiotropium Res\n pimat Inhaler and the risk of death in COPD. N. Engl. J. Med. 2013; 369: 1491–1501. Поступила 31.07.15 УДК 616.246036.126085.037
(check this in PDF content)